MiYOSMART
MiYOSMART IS THE SAFE, EASY TO USE, EFFECTIVE NON-INVASIVE WAY TO MANAGE MYOPIA IN CHILDREN
Proven to slow-down myopia progression by 60% *
Myopia is a global concern
An estimated 5 billion people, or half the global population, could be affected by myopia by 2050.1
Annual myopia progression rate is most rapid under 10 years of age. Significantly greater rates of progression can be seen especially in children with high myopia.
If left untreated, myopia can lead to lasting vision problems. But together we can tackle myopia in children.
A breakthrough spectacle lens
This revolutionary spectacle lens based on patented Defocus Incorporated Multiple Segments (D.I.M.S.) Technology was developed in cooperation with The Hong Kong Polytechnic University in 2014. MiYOSMART is easy to fit, just like regular single vision lenses. There are no limitations for the frame choice.
A revolutionary patented technology
With the exclusive non-invasive D.I.M.S. Technology, the lens corrects the visual defect on its entire surface and has a ring shaped treatment area to slow down myopia progression. The alternation of the focus area and defocus area provides clear vision and manages myopia simultaneously.
Designed to fit a child’s active life
MiYOSMART comes with an easy-to-wipe special anti-reflective, durable coating. With its Eye Shield, young patients get the added assurance of an impact resistant material and UV protection.
MiYOSMART’s Eye Shield
- Impact resistant
- Thin and light
- Comes with UV protection
Why MiYOSMART?
A child-friendly, safe and effective non-invasive method
During the 2-year clinical trial, no adverse event was reported that would have led to discontinuation of the treatment.
The lens is a very effective method to manage myopia and can be fitted to a child at any age like regular single vision lenses.
An award-winning, breakthrough ophthalmic lens, patented with D.I.M.S. technology
MiYOSMART’s efficacy is based on patent protected D.I.M.S. islands creating myopic defocus effect.
In 2018, the MiYOSMART lens won the Gold Prize, Grand Award & Special Gold Award Int’l Exhibition of Inventions of Geneva, Switzerland. In 2020, it won the Silmo d’Or Award in the Vision category at the Silmo Paris Optical Fair.
Appreciated by parents
MiYOSMART has data-driven proof of its effectiveness, with more than 500K patients/wearers.
Parents are happy with the value for money.
They appreciated the Eye Care Professional 6 month protocol and follow-up actions.
Learn More!
Learn more about how to bring MiyoSmart lenses into your myopia treatment practice today. Learn more
*Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. British Journal of Ophthalmology. Published Online First: 29 May 2019. doi: 10.1136/bjophthalmol-2018-313739 1 Holden B.A., Fricke T.R., Wilson D.A., Jong M., Naidoo K.S., Sankaridurg P., Wong T.Y., Naduvilath T.J., Resniko_ S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. American Academy of Ophthalmology. 05/2016, vol.123, no. 5, p.1036–1042. https://doi.org/10.1016/j.ophtha.2016.01.006. 2 years of data shows a 60% slowdown of myopia progression on average—myopia progression (SER) slowed by 59% and axial elongation (AL) decreased by 60% compared with those wearing single vision lenses. Myopia progression was completely stopped in 21.5% of those wearing MiYOSMART. The 2 year randomized controlled trial involved 160 children aged 8 to 13
1 Brien Holden Vision Institute; 2 Shanghai Eye Disease Prevention and Treatment Center https://guidelines.brienholdenvision.org, accessed 16.08.1018.
2 Lam CSY, Tang WC, Lee RPK, Chun RKM, To CH. A randomized clinical trial for myopia control – use of myopic defocus spectacle lens. 8th International Congress of Behavioral Optometry (ICBO), 26-29 of April 2018. Sydney, Australia. 8Sankaridurg P1, Tilia D1, Morton M1, Weng R1, Jong M1, Zhu F2. Guidelines for Myopia Management.